Información:
Error:
Palabras clave
PISHCHEVOD ×
- Clinical Trial (11)
- Adenocarcinoma (9)
- Treatment Form (3)
- Follow-Up Studies (3)
- Registration (2)
- Routine documentation (2)
- Quality of Life (1)
- Barrett Esophagus (1)
- On-Study Form (1)
- Disease Response (1)
- Diagnostic Imaging (1)
- Hypopharynx (1)
- Medical Oncology (1)
- Neoplasms (1)
Tabla de contenido
Modelos de datos seleccionados
Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.
13 Resultados de la búsqueda.
Itemgroup: Colon CA
Itemgroups: Header Module, Header, Disease Extent, Other Tumor Involvement, BASELINE LABS, EXAMINATIONS / CONSULTATIONS, General Conditions, Footer Module
Itemgroups: Header Module, Unnamed 1, Footer Module
Itemgroups: Header Module, Header, Current Disease Status, Events, New Primary Cancer, Additional Non Protocol Treatment, Toxicities, Adverse Events, Footer Module
Itemgroups: Header Module, Header, Current Disease Status, Events, Toxicities, LVEF Status, Adverse Events, Footer Module
Itemgroups: Protocol Administration, Pre-Treatment Characteristics, Certification Of Eligibility, Protocol Design (Stratification Factors), Companion Studies - Study 151007: Molecular Markers of Treatment Response (optional), Companion Studies - Study 71003: Correlation of QOL with Treatment Response and Validation of PRO-CTCAE (optional)
Itemgroups: Header Module, Endoscopy/Biopsy, Surgical Resection, Footer Module
Itemgroups: Protocol Information, SWOG PATIENT ID, DEMOGRAPHY, FOR SWOG INSTITUTIONS, PATIENT INFORMATION, Indicate how the patient answered the following questions on the consent form, Patient Eligibility
Itemgroups: RTOG clinical trial administrative data, Patient status, Disease Assessment, Disease Events, New Primary, Protocol Specific Adverse Events Evaluation, REPORT ALL CONTINUING OR NEW ADVERSE EVENTS, Footer
Itemgroup: Hypopharynx- Esophagram findings
Itemgroups: Header Module, EQ-5D Cover Sheet, EQ-5D Health State Measurement, Health State
Itemgroups: Header Module, Summary Of Maintenance Systemic Treatment, Treatment Summary, Therapy Modification, LVEF/ Other Toxicities, Adverse Events, Comments